Yasemin Eldemir Okay

Yasemin Eldemir Okay

Auto-generated profile, based on publicly available information

Yasemin Eldemir Okay

Faculty of Science, Department of Biology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
YOYasemin Eldemir Okay
Yasemin Eldemir Okay
IKİbRahim Halil Kenger
İbRahim Halil Kenger
HYHAMIT YILDIZ
HAMIT YILDIZ
MHMehmet Tahir Hüsunet
Mehmet Tahir Hüsunet
LDLale Dönbak
Lale Dönbak
AKAhmet Kayraldiz
Ahmet Kayraldiz
Two different drug groups, typical (classic) and atypical (new), are used in the treatment of schizophrenia. Aripiprazole, an atypical antipsychotic chemical, is the active ingredient of the drug Abilify. This study was conducted to determine the possible genotoxic effect of aripiprazole. For this purpose, four different doses of aripiprazole (5; 10; 20, and 40 µg/mL) were examined with Chromosome Abnormality (CA), Sister Chromatid Exchange (SCE), Micronucleus (MN) tests. Based on these tests, Proliferation Index (PI), Percent Abnormal Cells (AC), Mitotic Index (MI), Micronuclear Binuclear Cell (MNBN), and Nuclear Division Index (NDI) levels were determined in human peripheral lymphocytes treated for 24 and 48 hours. Also, to determine possible binding sites of Aripiprazole on B-DNA molecular docking analysis was performed using AutoDock 4.0 (B-DNA dodecamer, PDB code: 1BNA). Aripiprazole binds to B-DNA with a very significant free binding energy (–11.88 Kcal/mol). According to our study, aripiprazole did not significantly change SCE, CA, AC percentage, MN frequencies when compared with control. According to these results, aripiprazole does not have a genotoxic effect. At the same time, no significant change was observed in the PI, MI, and NDI frequencies when compared with the control. In line with these results, it was observed that the use of aripiprazole in the treatment of schizophrenia did not pose any acute genotoxic and cytotoxic risk.